skip to main content

Asymptomatic Hyperuricaemia — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCrystal ArthropathyAsymptomatic HyperuricaemiaSCE Rheumatology

A 55-year-old woman with rheumatoid arthritis and stage 4 chronic kidney disease has a persistently elevated serum urate concentration of 580 µmol/L. She has never had a gout flare, tophus or urinary tract calculus and has no malignancy, cytotoxic treatment or recognised urate-overproduction disorder. What is the most appropriate approach to urate-lowering therapy in current UK practice?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Do not start urate-lowering therapy solely for asymptomatic hyperuricaemia

The correct answer is C. This is isolated asymptomatic hyperuricaemia: there have been no gout flares, tophi, calculi or circumstances carrying a predictable risk of acute urate deposition. The UK allopurinol SmPC explicitly states that asymptomatic hyperuricaemia per se is generally not an indication for treatment. NICE recommends ULT for people with gout who also have CKD stages 3–5, but CKD alone does not convert asymptomatic hyperuricaemia into an indication. No validated serum-urate threshold, including 700 µmol/L, mandates treatment in an otherwise asymptomatic patient. Rheumatoid factor status is irrelevant. CKD-FIX also found no slowing of CKD progression with allopurinol in patients with stage 3–4 CKD and no gout. The raised urate should instead prompt review of reversible causes and appropriate CKD management.

Reference: Electronic Medicines Compendium. Allopurinol Tablets BP 100 mg, Summary of Product Characteristics, sections 4.1 and 4.4; revised 20 January 2025. https://www.medicines.org.uk/emc/product/7004/smpc